VANDA PHARMACEUTICALS INC. Contractual Obligation, to be Paid, Year Four
VANDA PHARMACEUTICALS INC. (VNDA) had Contractual Obligation, to be Paid, Year Four of $2.81 million as of 2018-12-31, per its 10-K filed 2019-02-19.
Discontinued › Notes › Commitment and Contingencies › Contractual Obligation, Fiscal Year Maturity › Contractual Obligation, to be Paid, Year Four and Five
us-gaap:ContractualObligationDueInFourthYear · last filed 2019-02-19
- 2018-12-31: Contractual Obligation, to be Paid, Year Four $2.81M.
- 2018-09-30: Contractual Obligation, to be Paid, Year Four $3.23M.
- 2018-06-30: Contractual Obligation, to be Paid, Year Four $3.23M.
- 2012-09-30: Contractual Obligation, to be Paid, Year Four $1.08M.
| Period end | Contractual Obligation, to be Paid, Year Four |
|---|---|
| 2018-12-31 | $2.81M 10-K · filed 2019-02-19 |
| 2018-09-30 | $3.23M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $3.23M 10-Q · filed 2018-08-02 |
| 2012-09-30 | $1.08M 10-Q · filed 2012-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |